Haematology · UK
Haematology treatment, by a consultant haematologist.
The whole specialty under one roof - anaemia to acute leukaemia, ITP to myeloma. British Society for Haematology guidance, NICE-approved therapy, and MDT-led cancer care at UK Cancer Alliance centres.
Indicative pricing
What private haematology treatment costs in the UK.
Indicative ranges across UK private providers. High-cost drugs (CAR-T, bispecifics, Casgevy) are commissioned via NHS England and NICE - we route you into the right pathway.
In short
£300–£500, results triaged .
| Service | Indicative range | Typical duration | Turnaround |
|---|---|---|---|
| New haematology consultation | £300–£500 | 45–60 min | Same visit |
| IV iron infusion (Ferinject / Monofer) | £600–£1,200 | 30–60 min | Same day |
| Anticoagulation clinic (DOAC / warfarin) | £250–£450 | 30 min | Same visit |
| Rituximab infusion (per cycle) | £1,800–£3,500 | Half-day | Same day |
| Bone marrow biopsy under LA | £900–£1,600 | 30 min | 7–14 days |
| Follow-up review | £200–£350 | 20–30 min | Same visit |
Prices vary by clinic, by consultant, and by drug regimen. High-cost therapies - CAR-T, bispecific antibodies, Casgevy gene therapy - are funded via the Cancer Drugs Fund and NICE TAs on defined pathways, not paid privately per cycle.
The problem
The right haematologist, the right MDT, the right drug.
Haematology moves fast - new NICE approvals, new bispecifics, new CAR-T indications every quarter. What matters is landing on the pathway that fits your disease and your fitness, without months of drift.
-
Abnormal bloods, no explanation?
A film, reticulocytes, haematinics, immunoglobulins and flow - targeted, not a shotgun panel.
-
Suspected haem cancer?
Straight to an MDT-led consultant, not to a waiting-list letter. Diagnosis, staging and plan in weeks.
-
Chronic condition, no continuity?
One named haematologist for your CLL, CML, ITP or myeloma - for years, not one appointment.
When it helps
When haematology treatment is the right step.
The conditions we treat most, from benign anaemia and clotting to leukaemia and myeloma - plus the one red flag that means A&E rather than an appointment.
-
Iron-deficiency anaemia
Low ferritin, fatigue, breathlessness - oral iron alternate-day dosing, or IV iron for intolerance, malabsorption, IBD or CKD.
-
VTE and atrial fibrillation
DOACs (apixaban, rivaroxaban, edoxaban, dabigatran) as NICE first-line; warfarin or LMWH where indicated.
-
ITP and autoimmune cytopenias
Steroids first-line, TPO-RAs (eltrombopag, romiplostim), rituximab, fostamatinib for refractory disease.
-
Bleeding disorders
Haemophilia A/B factor concentrate, emicizumab, VWF concentrate, DDAVP and tranexamic acid - coordinated with a haemophilia centre.
-
Sickle cell and thalassaemia
Hydroxycarbamide, transfusion, iron chelation (deferasirox, deferiprone), crizanlizumab, and - for eligible patients - Casgevy CRISPR gene therapy.
-
CLL, CML and myeloproliferative disease
Ibrutinib and acalabrutinib for CLL; imatinib, dasatinib or nilotinib for CML; ruxolitinib for myelofibrosis and PV.
-
Myeloma and lymphoma
Daratumumab, isatuximab, bispecific antibodies, autologous transplant, and CAR-T for relapsed or refractory disease.
-
Red flag: neutropenic sepsis
Fever above 38°C in anyone on chemotherapy is an emergency - A&E within the hour, not a clinic call.
Treatment options
Chemotherapy is only one of many options.
The main treatment families in modern UK haematology - from oral iron and DOACs to bispecifics, HSCT and CAR-T.
-
Iron therapy - oral and IV
Alternate-day ferrous sulphate for absorption; IV Ferinject, Monofer or Diafer where oral fails or malabsorption applies.
-
Anticoagulation and reversal
DOACs first-line, warfarin for mechanical valves or APLS, LMWH in pregnancy and cancer-associated VTE. PCC, andexanet alfa and idarucizumab for urgent reversal.
-
ITP and platelet therapy
Prednisolone, eltrombopag (Revolade), romiplostim (Nplate), rituximab, fostamatinib, and splenectomy as last-line.
-
Sickle cell and thalassaemia care
Hydroxycarbamide, exchange transfusion, iron chelation, crizanlizumab (Adakveo), voxelotor and Casgevy gene therapy for eligible patients.
-
Targeted therapy - TKIs and BTKis
Imatinib, dasatinib and nilotinib for CML; ibrutinib and acalabrutinib for CLL and MCL; venetoclax, ruxolitinib and FLT3 inhibitors as indicated.
-
Monoclonal and bispecific antibodies
Rituximab, obinutuzumab, daratumumab, elotuzumab, isatuximab, and bispecifics (blinatumomab, teclistamab, glofitamab, epcoritamab, elranatamab).
-
Cellular therapy - HSCT and CAR-T
Autologous transplant for myeloma and lymphoma; allogeneic for leukaemia, MDS, SCD and thalassaemia. CAR-T (Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, Carvykti) at commissioned UK centres.
-
Supportive care
Transfusion, G-CSF, TPO-RAs, antibiotic and antifungal prophylaxis, PCP cover (Septrin), and radiotherapy for lymphoma where appropriate.
Safety and what has changed
Haematology treatment in 2026 - honestly, and up to date.
Where the specialty actually is: CML now matches age-matched survival; CLL median survival is over 15 years; DLBCL is cured in 60–70% of cases; SCD and thalassaemia are potentially curable with HSCT or Casgevy. Supportive care carries the quality of life.
-
Alternate-day oral iron is better absorbed
Moretti Blood 2015 showed alt-day dosing gives better fractional absorption than daily - we use 200mg ferrous sulphate or fumarate alt-day as standard.
-
IV iron for the right patient
Ferinject, Monofer or Diafer are used where oral iron is not tolerated, does not absorb (IBD, coeliac, gastric surgery), or the patient has CKD.
-
DOACs are NICE first-line
For VTE and non-valvular AF, DOACs (apixaban, rivaroxaban, edoxaban, dabigatran) beat warfarin on convenience and bleeding profile.
-
Warfarin still matters
Mechanical heart valves, antiphospholipid syndrome, extreme BMI and severe renal impairment remain warfarin indications.
-
Emicizumab has changed haemophilia
Hemlibra (NICE TA577) is a subcutaneous bispecific that prevents bleeds in haemophilia A - with or without inhibitors - replacing three-times-weekly infusions.
-
CML now matches age-matched survival
TKIs have turned CML from a fatal disease into a chronic one - long-term survival on imatinib, dasatinib or nilotinib now approaches the general population.
-
CAR-T is real, and NICE-approved
Kymriah, Yescarta, Tecartus, Breyanzi, Abecma and Carvykti are all funded for defined indications - DLBCL, ALL, MCL and myeloma - via Cancer Alliance centres.
-
Gene therapy has arrived
Casgevy (CRISPR) is NICE-approved for sickle cell disease (TA1011) and β-thalassaemia (TA1012) - potentially curative for eligible patients.
-
Red flags
Fever on chemotherapy, sudden severe headache on anticoagulation, unexplained bruising or bleeding, or breathlessness at rest - all warrant same-day medical review.
Reading your clinic letter
Your haematology letter in four parts. Read the last one first.
Whichever condition and whichever treatment, the letter your haematologist sends you keeps to the same shape.
A quiet reminder
Haematology language is dense - WHO subtype, ISS stage, Deauville score - we translate it for you.
If you would like us to talk you through the letter before your next review, just ask.
- 01 Header
Diagnosis and staging
The exact haematological diagnosis - WHO subtype for cancers, plus staging (Ann Arbor, Binet, ISS, IPSS-R) where relevant.
- 02 Technique
Treatment plan and drug choice
The specific regimen, why it was chosen, the NICE TA it sits under, and - for cancer care - the MDT date and decision.
- 03 Findings
Response and monitoring
Molecular response (BCR-ABL for CML), MRD (for ALL, myeloma), imaging response (Deauville for lymphoma), or transfusion independence.
- 04 Impression
What comes next and when to worry
Read this first: the next appointment, the next scan or bloods, and the specific symptoms that mean you call the on-call haematology team.
Recognised by major UK insurers
Insurer cover for haematology varies by policy - outpatient consultations, day-unit infusions and bone marrow biopsies are typically covered. High-cost drugs (CAR-T, bispecifics, Casgevy) are funded via NHS pathways rather than PMI.
Frequently asked
Everything we get asked about haematology treatment.
Quick answers on iron therapy, anticoagulation, leukaemia cures, CAR-T access and what to do on chemotherapy.
-
What does a haematologist actually treat?
Everything to do with blood - anaemia, clotting problems (VTE, AF), bleeding disorders (haemophilia, VWD, ITP), sickle cell and thalassaemia, and blood cancers (leukaemia, lymphoma, myeloma, MDS, MPNs). Benign and malignant, adult and paediatric.
-
Is oral iron or IV iron better for iron deficiency?
Oral is first-line - alternate-day 200mg ferrous sulphate or fumarate absorbs better than daily dosing (Moretti Blood 2015). IV iron (Ferinject, Monofer, Diafer) is reserved for intolerance, malabsorption (IBD, coeliac), CKD, or where a rapid rise is needed.
-
DOAC or warfarin - which will I be put on?
For most VTE and non-valvular AF, NICE recommends a DOAC (apixaban, rivaroxaban, edoxaban or dabigatran) first-line. Warfarin remains standard for mechanical heart valves, antiphospholipid syndrome, extreme BMI and severe renal impairment. LMWH is used in pregnancy and cancer-associated VTE.
-
Can leukaemia really be cured?
For many patients, yes - or controlled indefinitely. CML on a TKI has survival that now matches the age-matched population. CLL patients have median survival over 15 years. Childhood ALL cures 90%+. Even AML and DLBCL have curative pathways for a substantial proportion. The picture is nothing like it was 20 years ago.
-
What is CAR-T therapy and can I have it in the UK?
CAR-T uses your own T-cells, re-engineered to target the cancer. Six products (Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, Carvykti) are NICE-approved and funded for defined indications - relapsed DLBCL, ALL, MCL and myeloma - delivered at commissioned centres including Kings, UCLH, Manchester, Leeds, Birmingham and Nottingham.
-
Is there a cure for sickle cell disease?
Allogeneic stem cell transplant has cured sickle cell for years, but needs a matched donor and carries risk. Casgevy (CRISPR gene therapy) is now NICE-approved (TA1011) as a potentially curative option for eligible patients aged 12+, delivered at UK Cancer Alliance centres.
-
How is haemophilia treated now?
Factor VIII or IX concentrate remains standard for on-demand and prophylactic care. For haemophilia A, emicizumab (Hemlibra, NICE TA577) is a subcutaneous bispecific antibody that prevents bleeds - including in patients with inhibitors - and has transformed quality of life.
-
What happens if I get a fever on chemotherapy?
A temperature above 38°C on chemotherapy is neutropenic sepsis until proven otherwise - go to A&E immediately, ideally within an hour of the fever starting. IV antibiotics within 60 minutes save lives. Do not wait for a clinic call-back.
Related treatments